It was a busy first week of February for both investors and central bankers. The Bank of England and the European Central Bank met this week and both left interest rates on hold, though signs suggest their respective policy paths could soon start to diverge.
Let’s begin with the Bank of England (BoE). At the previous meeting on 18 December, five policymakers outvoted four in favour of a 25bps rate cut to 3.75%. This time, the same five-to-four split held — but in favour of keeping rates unchanged. This outcome surprised markets, which had largely expected a seven‑to‑two vote to hold. Notably, Deputy Governor Sarah Breeden shifted her stance and supported a further rate cut, while Governor Bailey’s constructive remarks have boosted prospects of an interest cut at the March meeting. Overall, the tone was one of “good news”, with the Bank highlighting that inflation is projected to moderate by April, potentially creating room for additional easing. While inflation moderating and interest rate cuts are positives, the Bank of England did downgrade their growth outlook for 2026, while also raising their unemployment expectations.
The European Central Bank (ECB) kept interest rates unchanged at 2.15% for the fifth consecutive meeting, in a move that came as no surprise to markets. January’s inflation reading, released a day before the decision, eased to 1.7% and was acknowledged in the ECB’s commentary, though officials emphasised that inflation is expected to stabilise around target over the medium term. The broader eurozone economy has remained relatively resilient and stands to benefit from the gradual rollout of fiscal measures, particularly infrastructure and defence spending. This supports the view that the ECB may keep rates on hold for some time. However, policymakers also struck a cautious tone, noting that ongoing geopolitical tensions and uncertainty around global trade policy continue to pose risks to the outlook.
Novo Nordisk, the Danish pharmaceutical powerhouse, saw its shares tumble mid‑week, wiping almost $50 billion off its market capitalisation after issuing weaker‑than‑expected forecasts. The company now anticipates double‑digit declines in both profits and sales over 2026. It has also begun to lose ground to rival Eli Lilly in the US, where data shows Lilly’s obesity prescriptions gaining further traction. The outlook appears increasingly challenging for Novo, as the firm expects more competitors to enter the obesity drug market with copycat versions. It is estimated that more than 1.5 million Americans already use unofficial alternatives to branded weight‑loss medications, a figure that is likely to rise.
The US Government entered a brief shutdown over the weekend, an event that many barely noticed. For context, the previous shutdown revolved around a dispute over healthcare policy, lasting a record 43 days and costing the US economy an estimated $11 billion. While this latest shutdown is unlikely to have a comparable economic impact, it stemmed from an entirely different issue – immigration enforcement. Democrats pushed for President Trump to curb the authority of the Department of Homeland Security (DHS), which oversees federal immigration operations, and sought measures such as requiring ICE agents to wear body cameras, remove face coverings, and obtain judicial warrants. Public frustration has intensified following the second recent incident in which a US citizen was killed.
As a result of the shutdown, the release of the highly anticipated non‑farm payrolls report, normally published on the first Friday of each month, has been delayed until next Wednesday.
In Japan, attention is turning to Sunday’s election, where Prime Minister Takaichi is widely expected to secure a landslide victory. Her Liberal Democratic Party currently holds 198 seats in the lower house, but with the support of coalition partner Ishin, projections suggest they could reach 300 seats, comfortably above the 233 required for a majority. Such an outcome would give Takaichi the mandate to advance her ambitious expansionary fiscal agenda. However, this also raises concerns about the increased government bond issuance needed to fund the proposed spending, and the potential implications for monetary policy. Markets fear that the Bank of Japan may be compelled to accelerate its path of rate hikes if fiscal expansion adds to inflationary pressures.
By the close of play last Friday, silver had suffered its biggest ever one-day drawdown, falling close to 30%, with gold also falling significantly. Prices of precious metals have remained volatile this week, with big moves both up and down, with the price of silver currently around $75 an ounce, similar to where it started the week, but a long way from last Thursday’s intra-day high of $121.
It’s been a bruising week for software companies, with major concerns around their business models due to the rise of artificial intelligence. Anthropic’s Claude model is now seen as a direct threat to many software firms and data providers, and we witnessed billions of dollars of value removed from companies this week. Software companies continue to post strong earnings, but investors are worried whether this will continue, and given high starting valuations, we have seen prices correct.
The hyperscalers have also been in the news this week and again suffered weakness in share prices. Both Amazon and Alphabet (google) released results and outlined plans to significantly raise their capex plans for 2026. The market is beginning to be less forgiving on AI capex, with concerns over future returns – Amazon’s shares are down 9% in after-hours trading following their results.
The focus this week has been on the AI losers, and we have seen significant share price declines from a range of stocks. We have helped mitigate this risk through stock diversification, while exposing the portfolios to a range of assets, some of which are not linked to the AI theme. Undoubtedly the indiscriminate sell-off will create opportunities, but being selective is critical.
Nathan Amaning, Investment Analyst
Risk warning: With investing, your capital is at risk. The value of investments and the income from them can go down as well as up and you may not recover the amount of your initial investment. Certain investments carry a higher degree of risk than others and are, therefore, unsuitable for some investors.